1. 197TiPGLOW: Zolbetuximab + CAPOX compared with placebo + CAPOX as first-line treatment for patients with Claudin18.2+/HER2– Locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized phase III study. (24th November 2019) Authors: Xu, R-H; Dongsheng, Z; Ajani, J; Al-Batran, S-E; Bang, Y-J; Catenacci, D; Enzinger, P; Ilson, D; Kim, S; Lordick, F; Shitara, K; Van Cutsem, E; Arozullah, A; Wook Park, J; Shah, M Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 198TiPSPOTLIGHT: Comparison of zolbetuximab or placebo + mFOLFOX6 as first-line treatment in patients with claudin18.2+/HER2– locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (GEJ): A randomized phase III study. (24th November 2019) Authors: Yamaguchi, K; Shitara, K; Al-Batran, S-E; Bang, Y-J; Catenacci, D; Enzinger, P; Ilson, D; Kim, S; Lordick, F; Shah, M; Van Cutsem, E; Xu, R-H; Arozullah, A; Wook Park, J; Ajani, J Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 93O First results of phase I/II studies evaluating viral vector-based heterologous prime/boost immunotherapy against predicted HLA class I neoantigens demonstrate CD8 T cell responses in patients with advanced cancers. (15th December 2019) Authors: Johnson, M L; Spira, A; Carbone, D P; Drake, C; Henick, B; Ingham, M; Caldwell, K; Chan, S; Hart, M; Malloy, A; Maloney, E; Palmer, C; Yang, A; Zhong, M; Basciano, P; Bournazou, E; Ferguson, A R; Catenacci, D Journal: Annals of oncology Issue: Volume 30(2019)Supplement 11 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗